Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TRM003
MIFTS: 54

Tremor

Categories: Genetic diseases, Neuronal diseases, Oral diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Tremor

About this section

MalaCards integrated aliases for Tremor:

Name: Tremor 53 29 6 42
Tremors 6

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Neuronal diseases Oral diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

ICD10 32 R25.1
Sources

Summaries for Tremor

About this section
MedlinePlus : 42 What is a tremor? A tremor is a rhythmic shaking movement in one or more parts of your body. It is involuntary, meaning that you cannot control it. This shaking happens because of muscle contractions. A tremor is most often in your hands, but it could also affect your arms, head, vocal cords, trunk, and legs. It may come and go, or it may be constant. Tremor can happen on its own or be caused by another disorder. What are the types of tremor? There are several types of tremor, including Essential tremor, sometimes called benign essential tremor. This is the most common type. It usually affects your hands, but it can also affect your head, voice, tongue, legs, and trunk. Parkinsonian tremor, which is a common symptom in people who have Parkinson's disease. It is usually affects one or both hands when they are at rest, but it can affect the chin, lips, face, and legs. Dystonic tremor, which happens in people who have dystonia. Dystonia is a movement disorder in which you have involuntary muscle contractions. The contractions cause you to have twisting and repetitive movements. It can affect any muscle in the body. What causes tremor? Generally, tremor is caused by a problem in the deep parts of the brain that control movements. For most types, the cause is unknown. Some types are inherited and run in families. There can also be other causes, such as Neurologic disorders, including multiple sclerosis, Parkinson's disease, stroke, and traumatic brain injury Certain medicines, such as asthma medicines, amphetamines, caffeine, corticosteroids, and medicines used for certain psychiatric and neurological disorders Alcohol use disorder or alcohol withdrawal Mercury poisoning Hyperthyroidism (overactive thyroid) Liver or kidney failure Anxiety or panic Who is at risk for tremor? Anyone can get tremor, but it is most common in middle-aged and older adults. For certain types, having a family history raises your risk of getting it. What are the symptoms of tremor? Symptoms of tremor may include Rhythmic shaking in the hands, arms, head, legs, or torso Shaky voice Difficulty writing or drawing Problems holding and controlling utensils, such as a spoon How is tremor diagnosed? To make a diagnosis, your health care provider Will take your medical history Will do a physical exam, which includes checking Whether the tremor happens when the muscles are at rest or in action The location of the tremor How often you have the tremor and how strong it is Will do a neurological exam, including checking for Problems with balance Problems with speech Increased muscle stiffness May do blood or urine tests to look for the cause May do imaging tests to help figure out if the cause is damage in your brain May do tests which check your abilities to do daily tasks such as handwriting and holding a fork or cup May do an electromyogram. This is a test which measures involuntary muscle activity and how your muscles respond to nerve stimulation What are the treatments for tremor? There is no cure for most forms of tremor, but there are treatments to help manage symptoms. In some cases, the symptoms may be so mild that you do not need treatment. Finding the right treatment depends on getting the right diagnosis of the cause. Tremor caused by another medical condition may get better or go away when you treat that condition. If your tremor is caused by a certain medicine, stopping that medicine usually makes the tremor go away. Treatments for tremor where the cause is not found include Medicines. There are different medicines for the specific types of tremor. Another option is Botox injections, which can treat several different types. Surgery may be used for severe cases that do not get better with medicines. The most common type is deep brain stimulation (DBS). Physical, speech-language, and occupational therapy, which may help to control tremor and deal with the daily challenges caused by the tremor If you find that caffeine and other stimulants trigger your tremors, it may be helpful to cut them from your diet. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Tremor, also known as tremors, is related to fragile x tremor/ataxia syndrome and tremor, hereditary essential, 5. An important gene associated with Tremor is C19orf12 (Chromosome 19 Open Reading Frame 12), and among its related pathways/superpathways are Parkinson disease and Neuroscience. The drugs Donepezil and Ethanol have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and subthalamic nucleus, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

NINDS : 53 Tremor is an unintentional, rhythmic, muscle movement involving to-and-fro movements of one or more parts of the body. Most tremors occur in the hands, although they can also affect the arms, head, face, voice, torso, and legs. Generally, tremor is caused by a problem in the deep parts of the brain that control movements.  Some forms of tremor are inherited and run in families, while others have no known cause. Sometimes tremor is a symptom of another neurological disorder or a side effect of certain drugs, but the most common form occurs in otherwise healthy people. Excessive alcohol consumption or alcohol withdrawal can kill certain nerve cells, resulting in tremor, especially in the hand. Other causes include an overactive thyroid and the use of certain drugs. Tremor may occur at any age but is most common in middle-aged and older adults. There are several types of tremor, one of the most common of which is essential tremor (sometimes called benign essential tremor). The hands are most often affected but the head, voice, tongue, legs, and trunk may also be involved. Head tremor may be seen as a "yes-yes" or "no-no" motion. Onset is most common after age 40, although symptoms can appear at any age. Parkinsonian tremor is caused by damage to structures within the brain that control movement. The tremor is classically seen as a "pill-rolling" action of the hands but may also affect the chin, face, lips, and legs. Dystonic tremor occurs in individuals of all ages who are affected by dystonia, a movement disorder which causes muscles to be over-active, resulting in abnormal postures or sustained, unwanted movements.

Wikipedia : 74 A tremor is an involuntary, somewhat rhythmic, muscle contraction and relaxation involving oscillations... more...

Sources

Related Diseases for Tremor

About this section

Diseases in the Tremor family:

Tremor, Hereditary Essential, 1 Tremor, Hereditary Essential, 2
Tremor, Hereditary Essential, 3 Tremor, Hereditary Essential, 4
Tremor, Hereditary Essential, 5 Tremor, Hereditary Essential, 6
Essential Tremor Rare Tremor Disorder

Diseases related to Tremor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 853)
# Related Disease Score Top Affiliating Genes
1 fragile x tremor/ataxia syndrome 34.7 FRAXA FMR1
2 tremor, hereditary essential, 5 34.6 TENM4 DNAJC13
3 tremor, hereditary essential, 4 34.6 TENM4 FUS DNAJC13
4 tremor, hereditary essential, 1 34.5 TENM4 HTRA2 FUS DRD3
5 tremor, hereditary essential, 3 34.2 TENM4 HTRA2 FUS DNAJC13
6 tremor, hereditary essential, 2 34.2 TENM4 HTRA2 FUS ETM2 DRD3
7 essential tremor 33.2 TENM4 SNCA PRKN MAPT LRRK2 HTRA2
8 familial adult myoclonic epilepsy 32.9 SNCA SAMD12 CNTN2
9 parkinson disease 21 32.5 PRKN LRRK2 DNAJC13
10 multiple system atrophy 1 32.4 SNCA PRKN MAPT LRRK2 FMR1
11 von economo's disease 32.1 SNCA LRRK2
12 movement disease 32.0 SNCA PRKN MAPT LRRK2 GBA FUS
13 parkinson disease 2, autosomal recessive juvenile 32.0 SNCA PRKN LRRK2 HTRA2
14 dementia, lewy body 31.9 SNCA PRKN MAPT LRRK2 GBA FUS
15 parkinson disease, late-onset 31.9 SNCA PRKN MAPT LRRK2 HTRA2 GBA
16 parkinson disease 1, autosomal dominant 31.9 SNCA PRKN LRRK2 GBA
17 dystonia 31.8 PRKN LRRK2 FUS DRD3 C19orf12
18 leukoencephalopathy, hereditary diffuse, with spheroids 31.7 SNCA PRKN MAPT
19 neurodegeneration with brain iron accumulation 31.5 SNCA PRKN MAPT LRRK2 C19orf12
20 parkinson disease 15, autosomal recessive early-onset 31.5 SNCA PRKN LRRK2 C19orf12
21 amyotrophic lateral sclerosis 1 31.3 SNCA PRKN MT-ATP6 MAPT LRRK2 FUS
22 kufor-rakeb syndrome 31.2 SNCA PRKN LRRK2 C19orf12
23 fmr1 disorders 31.1 FRAXA FMR1
24 charcot-marie-tooth disease 30.6 SNCA PRKN MT-ATP6 LRRK2 HARS1 FUS
25 dysautonomia 30.6 SNCA GBA DNAJC13
26 sleep disorder 30.6 SNCA MAPT LRRK2
27 supranuclear palsy, progressive, 1 30.6 SNCA PRKN MAPT LRRK2 GBA FUS
28 autosomal dominant cerebellar ataxia 30.5 SNCA PRKN MAPT LRRK2 FUS FMR1
29 restless legs syndrome 30.4 SNCA PRKN MAPT FRAXA FMR1 DRD3
30 aceruloplasminemia 30.4 SNCA MT-ATP6 HARS1 C19orf12
31 rem sleep behavior disorder 30.4 SNCA PRKN MAPT LRRK2 GBA
32 corticobasal degeneration 30.3 MAPT LRRK2 GBA
33 aphasia 30.2 SNCA MAPT LRRK2 FUS
34 frontotemporal dementia 30.2 SNCA MAPT LRRK2 FUS
35 motor neuron disease 30.2 SNCA PRKN MAPT FUS
36 akinetic mutism 30.0 SNCA MAPT
37 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 30.0 SNCA MAPT FUS
38 neuronal intranuclear inclusion disease 29.9 SNCA MAPT
39 autism spectrum disorder 29.9 SNCA PRKN FUS FMR1 DRD3
40 postencephalitic parkinson disease 29.8 SNCA PRKN MAPT LRRK2
41 dementia 29.6 SNCA PRKN MT-ATP6 MAPT LRRK2 GBA
42 peripheral nervous system disease 29.6 SNCA PRKN MT-ATP6 LRRK2 HARS1
43 3-methylglutaconic aciduria, type iii 29.5 SNCA MT-ATP6 LRRK2 HTRA2
44 early-onset parkinson's disease 29.3 SNCA PRKN LRRK2 GBA DRD3 C19orf12
45 optic nerve disease 29.0 SNCA PRKN MT-ATP6 C19orf12
46 primary orthostatic tremor 12.6
47 fragile x-associated tremor/ataxia syndrome 12.6
48 myopathy, congenital, with tremor 12.6
49 tremor, hereditary essential, 6 12.5
50 neurodegeneration, childhood-onset, with ataxia, tremor, optic atrophy, and cognitive decline 12.3

Graphical network of the top 20 diseases related to Tremor:



Diseases related to Tremor
Sources

Symptoms & Phenotypes for Tremor

About this section

GenomeRNAi Phenotypes related to Tremor according to GeneCards Suite gene sharing:

26 (show all 19)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.62 GBA
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-118 9.62 GBA
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-132 9.62 DRD3
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-137 9.62 DRD3
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-151 9.62 GBA
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-159 9.62 DRD3
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 9.62 DRD3
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-175 9.62 HARS1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-29 9.62 HARS1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.62 GBA
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.62 HARS1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-51 9.62 DRD3 GBA
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-54 9.62 HARS1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.62 DRD3
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-67 9.62 DRD3
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-7 9.62 GBA
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.62 GBA
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-81 9.62 GBA
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-85 9.62 DRD3

MGI Mouse Phenotypes related to Tremor:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.36 CNTN2 DRD3 FMR1 GBA HTRA2 LRRK2
Sources

Drugs & Therapeutics for Tremor

About this section

Drugs for Tremor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 345)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Donepezil Approved Phase 4 120014-06-4 3152
2
Ethanol Approved Phase 4 64-17-5 702
3
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
4
Levodopa Approved Phase 4 59-92-7 6047
5
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
6
Carbidopa Approved Phase 4 28860-95-9 34359
7
Pramipexole Approved, Investigational Phase 4 104632-26-0 119570 59868
8
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
9
Memantine Approved, Investigational Phase 4 19982-08-2 4054
10
Levetiracetam Approved Phase 4 102767-28-2 441341
11
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
12
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
13
Clozapine Approved Phase 4 5786-21-0 2818
14
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
15
Methadone Approved Phase 4 76-99-3 4095
16
Entacapone Approved, Investigational Phase 4 130929-57-6 5281081
17
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
18
Morphine Approved, Investigational Phase 4 57-27-2 5288826
19
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
20
Racepinephrine Approved Phase 4 329-65-7 838
21
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
22
Apomorphine Approved, Investigational Phase 4 41372-20-7, 58-00-4 6005
23
Amantadine Approved Phase 4 768-94-5 2130
24
Nicotine Approved Phase 4 54-11-5 942 89594
25
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
26
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
27
Cefpirome Approved Phase 4 84957-29-9 5479539
28
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
29
Trimethobenzamide Approved, Investigational Phase 4 138-56-7 5577
30
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
31
4-Aminopyridine Approved Phase 4 504-24-5 1727
32
Histamine Approved, Investigational Phase 4 51-45-6 774
33
Ziprasidone Approved Phase 4 146939-27-7 60854
34
Sertraline Approved Phase 4 79617-96-2 68617
35
tannic acid Approved Phase 4 1401-55-4
36
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
37
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
38
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
39
Prilocaine Approved Phase 4 721-50-6 4906
40
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
41
Remifentanil Approved Phase 4 132875-61-7 60815
42
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
43
Iodine Approved, Investigational Phase 4 7553-56-2 807
44
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
45
Pimavanserin Approved, Investigational Phase 4 706779-91-1 16058810
46
Saxagliptin Approved Phase 4 361442-04-8 11243969
47
Zinc Approved, Investigational Phase 4 7440-66-6 32051
48
Metformin Approved Phase 4 657-24-9 14219 4091
49
Insulin aspart Approved Phase 4 116094-23-6 16132418
50
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253

Interventional clinical trials:

(show top 50) (show all 655)
# Name Status NCT ID Phase Drugs
1 A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control and Pari Nebulization for the Treatment of Adults With Moderate Asthma Unknown status NCT00385359 Phase 4 Albuterol
2 Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors Unknown status NCT03098368 Phase 4 Rotigotine;Placebo
3 A Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot Study Unknown status NCT02472210 Phase 4 Botulinum Toxin
4 A Randomized, Double-blind, Placebo Controlled, Crossover Study to Evaluate the Effect of Donepezil on Gait and Balance in Parkinson's Disease Unknown status NCT01521117 Phase 4 Donepezil
5 The Study to Assess the Effect of Trimetazidine on Index of Microcirculatory Resistance (IMR), Measured by Coronary Pressure and Temperature Wire, in Patients With Stable Coronary Artery Disease Unknown status NCT02107144 Phase 4 trimetazidine
6 Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone Unknown status NCT00480844 Phase 4 Sertindole;Risperidone
7 Propranolol and Botulinum Toxin for Essential Vocal Tremor Completed NCT02111369 Phase 4 Propranolol
8 A Multi-site, Double-blind, Randomized, Placebo-controlled, Crossover Study of Pregabalin (Lyrica, PGB) in the Treatment of Essential Tremor Completed NCT00584376 Phase 4 Pregabalin;Placebo
9 Atlas Predicted DBS Settings in Essential Tremor Completed NCT02678429 Phase 4
10 A Pilot Clinical Trial of Memantine for Essential Tremor Completed NCT00439699 Phase 4 Memantine
11 RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR) Completed NCT00998660 Phase 4
12 A 17 Week, Investigator-initiated, Single-center, Double-blind, Randomized, Placebo-controlled, Cross-over Trial of Pregabalin in Essential Tremor Completed NCT00646451 Phase 4 pregabalin;placebo capsules
13 An Open Label Evaluation of MIDI to Quantify Performance Change in Subjects With Musician's Dystonia After Treatment With Botulinum Toxin Type B (Myobloc ®). Completed NCT00208091 Phase 4 Botulinum toxin, type B
14 Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Oculopalatal Tremor: a Controled Open-label Study Completed NCT02466191 Phase 4 Memantine;Gabapentin
15 A Multicentre, Randomised, Open Label, Comparative Phase 4 Trial to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism in a General Neurologist Setting. Completed NCT00382967 Phase 4
16 A Comparison Study of the Efficacy and Tolerability Between Depakote ER and Depakote in the Acute Treatment of Mania and Mixed Mania Completed NCT00334347 Phase 4 Depakote ER;Depakote DR
17 A 16 WEEK, INVESTIGATOR-INITIATED, SINGLE-CENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF NAMENDA® (MEMANTINE HCL) FOR NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE Completed NCT00646204 Phase 4 Memantine;placebo
18 Comparison of Analgesic Effects of Gabapentin and Paracetamol in Patients With Hand Injury Completed NCT04068506 Phase 4 Gabapentin 600 mg Tab
19 Aripiprazole for Clozapine Associated Medical Morbidity Completed NCT00345033 Phase 4 Aripiprazole;Placebo
20 A Randomized, Double-blind, Placebo-controlled, Parallel Group Efficacy Study of Pramipexole and Placebo Administered Orally Over a 12 Week Treatment Phase in Parkinson's Disease Patients With Stable Motor Function and Depressive Symptoms Completed NCT00297778 Phase 4 Pramipexole
21 Effect of Duodenal Levodopa Infusion on Quality of Life and Autonomic Dysfunction in Patients With Parkinson's Disease Completed NCT00914134 Phase 4 Levodopa infusion
22 A Prospective, Multi-center, Randomized, Open-label Study With Blinded Raters to Evaluate the Effects of Immediate Versus Delayed Switch to Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-dose Wearing Off Completed NCT00219284 Phase 4 Carbidopa/levodopa/entacapone
23 A Pilot Study of Corticosteroid-Free, Calcineurin-Sparing Immunosuppression Protocol for HLA-Identical Living Donor Renal Transplant Recipient Completed NCT00352092 Phase 4 calcineurin inhibitor;sirolimus;mycophenolate mofetil
24 The Effects of Levetiracetam on Alcohol Dependent Subjects Completed NCT00325182 Phase 4 Levetiracetam
25 Effects of Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity (Local Field Potentials) Measured Through Implanted Stimulators Completed NCT02256319 Phase 4 Dexmedetomidine;Propofol
26 Randomized Double-Blind Placebo-Controlled Trial of Lubiprostone in the Treatment of Constipation Associated With Parkinson's Disease Completed NCT00908076 Phase 4 LUBIPROSTONE
27 A Multicenter, Open-Label, Two-Arm Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management Completed NCT03103919 Phase 4 Rotigotine
28 Liquid Risperidone in the Treatment of Acute Agitation in Psychiatrically Hospitalized Children Completed NCT00790075 Phase 4 risperidone
29 Multimodal Analgesic Technique for Control of Post-laproscopy Abdominal Pain in Patient Undergoing Diagnostic Gynacological Laproscopy. A Randomized Controlled Trial Completed NCT03241602 Phase 4 Intraperitoneal lidocaine
30 RNS® System Long-term Treatment (LTT) Clinical Investigation Completed NCT00572195 Phase 4
31 The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
32 The Impact of the Prophylactic or Therapeutic Application of Bryophyllum on Preterm Delivery - a Prospective Study Completed NCT00163579 Phase 4 Bryophyllum
33 A Double-Blind, Placebo-Controlled Trial of Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment: Bergman's Minimal Model Analysis Completed NCT00337350 Phase 4 rosiglitazone;placebo
34 Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease. Completed NCT00640159 Phase 4 Zelapar
35 Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration Completed NCT00280514 Phase 4 cefpirome and moxifloxacin administration
36 A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action Completed NCT01770145 Phase 4 APOKYN;L-dopa;Trimethobenzamide
37 The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Ventrucular Septal Defect Patients With Persistant or Surgically Corrected Conditions - The VENTI Trial Completed NCT02914652 Phase 4 Salbutamol;Norflouran (Placebo Evohaler(R) )
38 A Phase IV Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis Completed NCT02208050 Phase 4 Fampridine;Placebo
39 A Comparison of Bupropion SR and Placebo for Smoking Cessation Completed NCT00176449 Phase 4 Bupropion SR;Placebo Oral Tablet
40 Efficacy of Nebulised Hypertonic Saline (3%) Among Children With Mild to Moderately Severe Bronchiolitis - A Double Blind Randomized Controlled Trial. Completed NCT01276821 Phase 4 L-Epinephrine and Normal Saline (0.9%);L-Epinephrine and Hypertonic Saline (3%)
41 Randomized Controlled Trial of The Safety and Efficacy of Aripiprazole VS Ziprasidone in Schizophrenic Patients With Metabolic Syndrome and Diabetes Mellitus. Completed NCT01714011 Phase 4 Ziprasidone;Aripiprazole
42 QUALITY OF RECOVERY AFTER INTRAOPERATIVE MORPHINE OR METHADONE IN PATIENTS UNDERGOING LAPAROSCOPIC CHOLECYSTECTOMY Completed NCT03045133 Phase 4 Methadone;Morphine
43 A Study of Sertraline to Prevent PTSD Completed NCT00182078 Phase 4 Placebo;Sertraline
44 Dosing Strategies for de Novo Once-daily Extended Release Tacrolimus (LCPT) in Kidney Transplant Recipients Recruiting NCT03713645 Phase 4 Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg/kg/day initiated within post-operative day 3 after kidney transplant
45 Lidocaine Versus Ketorolac for the Management of Renal Colic Recruiting NCT03137498 Phase 4 Lidocaine;Ketorolac
46 A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients Recruiting NCT03461445 Phase 4 Envarsus;IR Tacrolimus
47 Effects of Anesthesia Drugs on Neuronal Activity in the Basal Ganglia and Thalamus During Deep Brain Stimulation Electrode Implantation Surgery Recruiting NCT03283150 Phase 4 Remifentanil;Propofol;Dexmedetomidine
48 Peripheral Nerve Blocks for Major Lower Extremity Amputations Recruiting NCT03174782 Phase 4 Bupivacaine;Saline Solution
49 A Placebo-controlled, Double-blind, Randomized, Cross Over Pilot Study of the Efficacy and Tolerability of Abobotulinum Toxin A (Dysport) as a Treatment for Task-dependent Upper Limb Tremor Active, not recruiting NCT03136341 Phase 4 Abobotulinum toxin A
50 A Pilot Study of Stable Kidney Transplant Recipients Taking Tacrolimus With CNS Symptoms Switched to Envarsus Active, not recruiting NCT03270462 Phase 4 Envarsus XR

Search NIH Clinical Center for Tremor

Sources

Genetic Tests for Tremor

About this section

Genetic tests related to Tremor:

# Genetic test Affiliating Genes
1 Tremor 29
Sources

Anatomical Context for Tremor

About this section

MalaCards organs/tissues related to Tremor:

40
Brain, Testes, Subthalamic Nucleus, Thalamus, Liver, Thyroid, Cortex
Sources

Publications for Tremor

About this section

Articles related to Tremor:

(show top 50) (show all 22104)
# Title Authors PMID Year
1
Tactile and proprioceptive dysfunction differentiates cervical dystonia with and without tremor. 61 42
31937622 2020
2
Teaching Video NeuroImages: Tardive diaphragmatic tremor. 42 61
32001515 2020
3
Open-label pilot clinical trial of citicoline for fragile X-associated tremor/ataxia syndrome (FXTAS). 42 61
32053612 2020
4
Clinicopathological findings of a long-term survivor of V180I genetic Creutzfeldt-Jakob disease. 61
32178563 2020
5
Injury of the dentatorubrothalamic tract in patients with post-traumatic tremor following mild traumatic brain injury: a case-control study. 61
32394963 2020
6
NUS1 mutation in a family with epilepsy, cerebellar ataxia, and tremor. 61
32485575 2020
7
A novel LC-MS/MS analytical method for detection of articaine and mepivacaine in blood and its application to a preliminary pharmacokinetic study. 61
32408062 2020
8
Calpain mediated expansion of CD4+ cytotoxic T cells in rodent models of Parkinson's disease. 61
32302678 2020
9
Long-term efficacy and cognitive effects of voltage-based deep brain stimulation for drug-resistant essential tremor. 61
32480294 2020
10
Pramipexole Reduces zif-268 mRNA Expression in Brain Structures involved in the Generation of Harmaline-Induced Tremor. 61
32172399 2020
11
Robotic Approach to Outpatient Inguinal Hernia Repair. 61
32380165 2020
12
Development of the reverse genetics system for emerging atypical porcine pestivirus using in vitro and intracellular transcription systems. 61
32311384 2020
13
Human brain connectivity: Clinical applications for clinical neurophysiology. 61
32417703 2020
14
The Occurrence of FUS Mutations in Pediatric Amyotrophic Lateral Sclerosis: A Case Report and Review of the Literature. 61
32281455 2020
15
Potential role for rTMS in treating Primary Orthostatic Tremor. 61
32422175 2020
16
F-18 FDG PET brain imaging in symptomatic arthroprosthetic cobaltism. 61
31863138 2020
17
Optical Coherence Tomography Guided Robotic Needle Insertion for Deep Anterior Lamellar Keratoplasty. 61
31751219 2020
18
Genetic characterization and recombination analysis of atypical porcine pestivirus. 61
32087344 2020
19
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. 61
32562684 2020
20
Distinct non-motor features of essential tremor with head tremor patients. 61
32176316 2020
21
Anesthesia considerations of magnetic resonance imaging-guided focused ultrasound thalamotomy for essential tremor: a case series. 61
32291631 2020
22
Relation between cognitive and cerebello-thalamo-cortical functions in healthy elderly people: Evidence from the Yakumo Study. 61
30689412 2020
23
Tremor pathophysiology: lessons from neuroimaging. 61
32520800 2020
24
Proteomic Analysis of the Cerebrospinal Fluid in Patients With Essential Tremor Before and After Deep Brain Stimulation Surgery: A Pilot Study. 61
31755628 2020
25
Correlation of proximal and distal muscle strength with upper limb functional ability in patients with essential tremor. 61
30565036 2020
26
Azathioprine-Induced Tremor: A Rare, Dose-Dependent Side Effect of Azathioprine in a Patient With Active Crohn Disease. 61
32444877 2020
27
Cryptococcus Meningitis Can Co-occur with Anti-NMDA Receptor Encephalitis. 61
32522922 2020
28
New onset neurologic events in people with COVID-19 infection in three regions in China. 61
32554771 2020
29
Familial cortical myoclonic tremor with epilepsy: TTTCA/TTTTA repeat expansions and expanding phenotype in two Chinese families. 61
32194077 2020
30
Non-invasive brain stimulation and kinesiotherapy for treatment of focal dystonia: Instrumental analysis of three cases. 61
32284289 2020
31
Pallidal Activity in Cervical Dystonia with and Without Head Tremor. 61
32095996 2020
32
Diagnostic Delay in Cervical Dystonia: Dystonia with Antecedent Essential Tremor? 61
32562458 2020
33
Defective Human Motion Perception in Cervical Dystonia Correlates With Coexisting Tremor. 61
32199036 2020
34
Oromandibular dystonia: a diagnosis not to miss. 61
32143935 2020
35
Atypical pantothenate kinase-associated neurodegeneration with PANK2 mutations : clinical description and a review of the literature. 61
32310012 2020
36
NUBPL mitochondrial disease: new patients and review of the genetic and clinical spectrum. 61
32518176 2020
37
Early-onset cerebellar ataxia in a patient with CMT2A2. 61
32532879 2020
38
Topiramate-Responsive Tremor in a Novel Pathogenic Variant of SPG15 Patient. 61
32501858 2020
39
Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. 61
32546134 2020
40
Genotype-phenotype variable correlation in Wilson disease: clinical history of two sisters with the similar genotype. 61
32532207 2020
41
Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): Pathophysiology and Clinical Implications. 61
32575683 2020
42
An explanation of the mechanisms underlying fragile X-associated premature ovarian insufficiency. 61
32377997 2020
43
Elevated FMR1-mRNA and lowered FMRP - A double-hit mechanism for psychiatric features in men with FMR1 premutations. 61
32576818 2020
44
Autofluorescence-based analyses of intranuclear inclusions of Fragile X-associated tremor/ataxia syndrome. 61
32486839 2020
45
Study of telomere length in men who carry a fragile X premutation or full mutation allele. 61
32533363 2020
46
Tremor and ataxia in COVID-19. 61
32571554 2020
47
Motor outcomes and adverse effects of deep brain stimulation for dystonic tremor: A systematic review. 61
32559631 2020
48
Novel MTMR2 mutation causing severe Charcot-Marie-Tooth type 4B1 disease: a case report. 61
32488727 2020
49
NOTCH2NLC GGC repeat expansions are associated with sporadic essential tremor: Variable disease expressivity on long-term follow-up. 61
32495371 2020
50
Delayed Diagnosis of West Nile Virus Infection in a Kidney Transplant Patient Due to Inaccuracies in Commonly Available Diagnostic Tests. 61
30602362 2020
Sources

Variations for Tremor

About this section

ClinVar genetic disease variations for Tremor:

6 (show all 15) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MT-ATP6 NC_012920.1:m.9032T>CSNV Pathogenic 693061 MT:9032-9032 MT:9032-9032
2 HARS1 NM_002109.6(HARS1):c.616G>T (p.Asp206Tyr)SNV Pathogenic 804285 5:140057507-140057507 5:140677922-140677922
3 HARS1 NM_002109.6:c.730delGdeletion Pathogenic 804286
4 LOC101927919 , NUS1 , SLC35F1 NC_000006.11:g.(117961791_117961792)_(118280043_118280044)deldeletion Pathogenic 180225 6:117961791-118280044 6:117640628-117958881
5 LOC101927919 , NUS1 NC_000006.11:g.(117971549_117971550)_(118218719_118218720)deldeletion Pathogenic 180226 6:117971549-118218720 6:117650386-117897557
6 covers 24 genes, none of which curated to show dosage sensitivity NC_000006.11:g.(116681080_116735056)_(119687719_119775014)deldeletion Pathogenic 180227 6:116681080-119775014
7 TMEM67 NM_153704.6(TMEM67):c.1321C>T (p.Arg441Cys)SNV Pathogenic/Likely pathogenic 217725 rs752362727 8:94798483-94798483 8:93786255-93786255
8 TMEM67 NM_153704.6(TMEM67):c.1843T>C (p.Cys615Arg)SNV Pathogenic/Likely pathogenic 1383 rs201893408 8:94808198-94808198 8:93795970-93795970
9 C19orf12 NM_001256047.1(C19orf12):c.172G>A (p.Gly58Arg)SNV Pathogenic/Likely pathogenic 31157 rs515726205 19:30193873-30193873 19:29702966-29702966
10 GBA NM_000157.4(GBA):c.1093G>A (p.Glu365Lys)SNV risk factor 199044 rs2230288 1:155206167-155206167 1:155236376-155236376
11 MPZ NM_000530.8(MPZ):c.699T>G (p.Ser233Arg)SNV Likely pathogenic 374017 rs1057518839 1:161275714-161275714 1:161305924-161305924
12 C19orf12 NM_001256047.1(C19orf12):c.391A>G (p.Lys131Glu)SNV Conflicting interpretations of pathogenicity 31158 rs146170087 19:30193654-30193654 19:29702747-29702747
13 GLI2 NM_001374353.1(GLI2):c.2593A>T (p.Thr865Ser)SNV Uncertain significance 523482 rs1332140763 2:121746134-121746134 2:120988558-120988558
14 ADGRV1 NM_032119.4(ADGRV1):c.5188A>T (p.Ile1730Phe)SNV Uncertain significance 523543 rs1554079046 5:89971137-89971137 5:90675320-90675320
15 CACNA1H NM_021098.3(CACNA1H):c.6884C>T (p.Ser2295Phe)SNV Uncertain significance 523531 rs772718469 16:1270816-1270816 16:1220816-1220816

Copy number variations for Tremor from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 247217 9 129375646 129461836 Deletion FAM129B Tremor
2 247222 9 129375646 129461836 Deletion STXBP1 Tremor
Sources

Expression for Tremor

About this section
Search GEO for disease gene expression data for Tremor.
Sources

Pathways for Tremor

About this section

Pathways related to Tremor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Parkinson disease 36
Show member pathways
 12.6 SNCA PRKN MT-ATP6 MAPT LRRK2 HTRA2
2
Neuroscience 4
11.63 SNCA PRKN MAPT LRRK2 FMR1 CNTN2
3
Parkinsons Disease Pathway 1
11.18 SNCA PRKN LRRK2 HTRA2
Sources

GO Terms for Tremor

About this section

Cellular components related to Tremor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell projection GO:0042995 9.95 TMEM67 TENM4 MAPT LRRK2 FMR1 DRD3
2 mitochondrion GO:0005739 9.86 SNCA PRKN MT-ATP6 MAPT LRRK2 HTRA2
3 synapse GO:0045202 9.85 SNCA PRKN LRRK2 FMR1 DRD3 CNTN2
4 axon GO:0030424 9.72 SNCA MAPT LRRK2 FMR1 CNTN2
5 synaptic vesicle membrane GO:0030672 9.58 SNCA LRRK2 DRD3
6 inclusion body GO:0016234 9.46 SNCA LRRK2
7 growth cone GO:0030426 9.46 SNCA MAPT LRRK2 FMR1
8 glial cell projection GO:0097386 9.43 MAPT FMR1
9 neuron projection GO:0043005 9.43 TENM4 PRKN MAPT LRRK2 FMR1 CNTN2
10 neuronal cell body GO:0043025 9.1 SNCA MAPT LRRK2 FUS FMR1 CNTN2

Biological processes related to Tremor according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 response to oxidative stress GO:0006979 9.83 PRKN LRRK2 C19orf12
2 cellular response to oxidative stress GO:0034599 9.78 SNCA LRRK2 HTRA2
3 negative regulation of protein phosphorylation GO:0001933 9.77 SNCA PRKN LRRK2
4 regulation of autophagy GO:0010506 9.76 PRKN MAPT LRRK2
5 positive regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032436 9.75 PRKN LRRK2 GBA
6 learning GO:0007612 9.72 PRKN DRD3 CNTN2
7 mitochondrion organization GO:0007005 9.71 PRKN LRRK2 HTRA2 GBA
8 adult locomotory behavior GO:0008344 9.69 SNCA PRKN HTRA2
9 regulation of neuronal synaptic plasticity GO:0048168 9.65 SNCA CNTN2
10 autophagy GO:0006914 9.65 PRKN LRRK2 GBA DRD3 C19orf12
11 regulation of neuron death GO:1901214 9.64 SNCA LRRK2
12 behavioral response to cocaine GO:0048148 9.64 SNCA DRD3
13 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.63 PRKN LRRK2
14 cellular protein catabolic process GO:0044257 9.63 PRKN HTRA2
15 positive regulation of proteasomal protein catabolic process GO:1901800 9.62 PRKN FMR1
16 cellular response to dopamine GO:1903351 9.62 PRKN LRRK2
17 negative regulation of voltage-gated calcium channel activity GO:1901386 9.61 FMR1 DRD3
18 regulation of dopamine secretion GO:0014059 9.61 SNCA PRKN DRD3
19 supramolecular fiber organization GO:0097435 9.6 SNCA MAPT
20 regulation of mitochondrial fission GO:0090140 9.57 MAPT LRRK2
21 cellular response to manganese ion GO:0071287 9.56 PRKN LRRK2
22 intracellular distribution of mitochondria GO:0048312 9.54 MAPT LRRK2
23 regulation of neurotransmitter secretion GO:0046928 9.54 SNCA PRKN FMR1
24 protein localization to mitochondrion GO:0070585 9.52 PRKN LRRK2
25 synaptic transmission, dopaminergic GO:0001963 9.5 SNCA PRKN DRD3
26 dopamine uptake involved in synaptic transmission GO:0051583 9.49 SNCA PRKN
27 positive regulation of dopamine receptor signaling pathway GO:0060161 9.48 LRRK2 DRD3
28 regulation of synaptic vesicle transport GO:1902803 9.46 PRKN LRRK2
29 dopamine metabolic process GO:0042417 9.33 SNCA PRKN DRD3
30 regulation of locomotion GO:0040012 9.13 SNCA LRRK2 DRD3
31 negative regulation of neuron death GO:1901215 9.02 SNCA PRKN LRRK2 HTRA2 GBA

Molecular functions related to Tremor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 microtubule binding GO:0008017 9.56 SNCA MAPT LRRK2 FMR1
2 dynein complex binding GO:0070840 9.37 SNCA FMR1
3 actin binding GO:0003779 9.35 SNCA PRKN MYBPC1 MAPT LRRK2
4 tubulin binding GO:0015631 9.33 PRKN MAPT LRRK2
5 phospholipase binding GO:0043274 9.32 SNCA PRKN
6 identical protein binding GO:0042802 9.32 TENM4 SNCA PRKN MAPT LRRK2 HTRA2
Sources

Sources for Tremor

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....